Healthcare News, Deals, and Investments Update August 3rd, 2026
by Spenser Lin
Spenser Lin No Comments
LECO_Weekly-Healthcare-News_8-3-2026Download
  1. Lawrence, Evans & Co. Closes $30M Cross-Border Refinance and Growth Acquisition Financing for Expanding Healthcare RCM Platform Lawrence, Evans & Co. (LECO) announced the closing of a refinance and growth acquisition financing for a fast-growing healthcare revenue cycle management platform. LECO led the transaction while coordinating multiple acquisitions across several countries and managing the related overseas legal and regulatory requirements. The $30M financing supported the owner’s non-dilutive refinancing and acquisition line of credit needs, letting the company fund growth without giving up equity. Neil Johnson, Managing Partner at Lawrence, Evans & Co., LLC, led the transaction. The deal reflects LECO’s work advising healthcare and technology companies on complex, cross-border capital solutions tied to acquisition strategies. (Link)
  2. Clearview Capital agreed to exit Advantage Behavioral Health in a $610 million municipal-bond-financed sale to nonprofit QCF/I, Inc. Connecticut-based private equity firm Clearview Capital agreed to sell New Jersey-headquartered Advantage Behavioral Health, an operator of mental health centers and sober-living facilities, to nonprofit QCF/I, Inc., which is funding the purchase through a planned $610 million unrated municipal bond issuance. Clearview, together with ABH’s founders and management, is expected to receive roughly $415 million at closing, with up to $100 million more tied to performance milestones. The sale comes just over a year after Clearview recapitalized the company. ABH expects to treat more than 500,000 patients annually and generate about $170 million in revenue and $78 million of EBITDA this year. This is QCF’s fourth and largest acquisition. (Link)
  3. Blue Sea Capital closed an oversubscribed continuation vehicle for One Physics, led by Apogem Capital, Churchill Asset Management, Dextra Partners and Future Standard. Blue Sea Capital, a West Palm Beach private equity firm with over $1.5 billion in assets under management focused on middle-market healthcare companies valued up to $500 million, closed its first continuation vehicle to extend its partnership with One Physics. The meaningfully oversubscribed transaction was led by Apogem Capital, Churchill Asset Management, Dextra Partners and Future Standard, with participation from Abbott Capital and Twin Bridge Capital Partners. Both Blue Sea and One Physics management reinvested significantly. Towson, Maryland-based One Physics is North America’s leading outsourced medical physics provider, with more than 210 physicists delivering regulatory-mandated testing and compliance services to hospitals, imaging centers and cancer facilities. (Link)
  4. Kettering Health signed a non-binding letter of intent for Knox Community Hospital to join its nonprofit system. Knox Community Hospital, a 99-bed nonprofit hospital in Mount Vernon, Ohio, signed a non-binding letter of intent to join Kettering Health, a nonprofit system headquartered in Kettering, Ohio. The two Ohio organizations entered exclusive negotiations toward a definitive agreement by early fall, with closing targeted by the end of 2026 pending regulatory review. As a nonprofit combination, no purchase price applies. Kettering Health committed to significant capital investment in Knox’s service area over the 10 years after closing, including a new EHR system and workforce support. Kettering operates 14 medical centers and more than 100 outpatient locations across western Ohio; Knox would be its farthest medical center beyond southwest Ohio. (Link)
  5. Health Catalyst Capital acquired a leading Midwest provider of psychiatric medical care for elderly and disabled adults to fund regional expansion. New York-based private equity firm Health Catalyst Capital acquired a clinician-led Midwest psychiatric medical care provider serving elderly and disabled adults across long-term care facilities and hospitals. Financial terms were not disclosed, and the target remains unnamed. Both parties are private. Health Catalyst Capital invests in healthcare services and technology businesses and leverages relationships with over 250 healthcare and technology enterprises, driving value by helping portfolio companies integrate AI and build commercial relationships. With the backing, the practice plans to expand its regional footprint into additional long-term care and hospital settings, a segment seeing rising demand as the population ages. (Link)
  6. LiveWell Partners, backed by Encore Management Group, acquired Michigan Community VNA Home Health and Hospice. LiveWell Partners, a St. Louis-based home health and hospice platform backed by private equity firm Encore Management Group, acquired Detroit-based Michigan Community VNA Home Health and Hospice. Financial terms were undisclosed. Founded in 2023, LiveWell has grown largely through Midwest acquisitions and now operates across Illinois, Kansas, Michigan, Missouri and Ohio; this is its third Michigan deal. Under LiveWell’s operating model, acquired organizations keep their community identities and leadership while gaining shared clinical, operational and technology resources. Michigan Community VNA, which traces its roots to 1898, provides skilled home health, therapies, palliative care and hospice across metropolitan Detroit and complements LiveWell’s existing regional density strategy. (Link)
  7. Nexus acquired Telemetrix RPM to extend its clinical care operating system from the hospital to the home. Nexus, formerly Nexus Bedside, acquired Telemetrix RPM, a remote patient monitoring and chronic care management company operating inside native Epic workflows. Financial terms were undisclosed, and both companies are private. The deal, which closed July 23 in Cleveland, unifies inpatient coordination, remote monitoring, chronic care management and cardiac AI into a single workflow. Akram Boutros, MD, serves as CEO of both entities; former Telemetrix CEO Burley Wright becomes COO of Nexus, and founder Bret Shillingstad, MD, stays on as chief medical officer of both. The combination reflects a broader push among health tech providers toward integrated platforms connecting inpatient and post-acute care. (Link)
  8. ARC Health partnered with Old Greenwich, Connecticut-based The Waverly Group to expand collaborative pediatric care. ARC Health, a national network of mental healthcare providers, partnered with The Waverly Group, a multidisciplinary pediatric practice in Old Greenwich, Connecticut. Financial terms were undisclosed, and both organizations are private. Waverly becomes ARC Health’s second Connecticut partner and fourth in the greater New York metro area, offering ABA and behavior therapy, occupational and physical therapy, psychotherapy, psychological testing, speech therapy and related services. The practice keeps its identity and clinical leadership while gaining ARC Health’s operational resources and national provider network. CEO Vince Morra emphasized the coordinated, multidisciplinary model. ARC Health operates a provider-centric structure in which partners become equity-owning members. (Link)
  9. Included Health signed a definitive agreement to acquire Firefly Health to build a clinically integrated health plan alternative for employers. Included Health, an AI-native virtual care and navigation company, agreed to acquire Firefly Health, a clinically integrated health plan and advanced primary care provider serving more than 20,000 members through a network of over 2,300 providers. Financial terms were not disclosed, and the deal is expected to close in the third quarter of 2026 subject to regulatory review. Both companies are privately held. The combination pairs Included Health’s clinician-in-the-loop platform with Firefly’s plan design and near- and in-home network, targeting employers facing steep medical cost trends. Firefly reported 15%+ total cost of care savings and 90% member satisfaction in 2025. (Link)
  10. Graham Partners acquires TechData Service Company to form Quantive Intelligence platform Private equity firm Graham Partners acquired TechData Service Company and combined it with LLX Solutions and R Square Technology to form Quantive Intelligence, a decision-sciences platform focused on biostatistics, statistical programming, and clinical data services. The platform serves pharmaceutical and biotechnology sponsors with submission-stage clinical development support. Headquartered in King of Prussia, Pennsylvania, with operations in Massachusetts, Greater China, and India, the combined organization employs more than 700 people. Financial terms were not disclosed. The transaction closed July 1, 2026. (Link)
  11. Vital Infrastructure Property Trust acquired an EmblemHealth-leased Brooklyn medical office building for approximately $89 million. Toronto-based healthcare infrastructure REIT Vital Infrastructure Property Trust acquired the roughly 140,000-square-foot East New York Health Hub at 101 Pennsylvania Avenue in Brooklyn for about $89 million (C$126.7 million), or more than $635 per square foot, from developer Dominion Management Company. (The linked headline labels the buyer “Global Healthcare REIT,” but the acquirer is Vital Infrastructure Property Trust.) The trophy-quality building is leased long-term to nonprofit insurer EmblemHealth, with additional tenants including AdvantageCare Physicians, New York Cancer & Blood Specialists and Quest Diagnostics. CEO Zach Vaughan called it a step in Vital’s strategy to re-enter the large, fragmented U.S. healthcare real estate market. (Link)
  12. Novanta Inc. (NASD: NOVT) completed its ~$1.2 billion acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta (NASD: NOVT) completed the acquisition of Riverpoint Medical from Washington, D.C.-area private investment firm Arlington Capital Partners, paying approximately $1.2 billion in cash at closing plus a potential $250 million milestone payment due by early January 2027. Riverpoint is a category leader in minimally invasive surgical consumables, including surgical fibers for sports medicine, trauma and cardiovascular applications, with facilities in Portland, Oregon and San Jose, Costa Rica. A Novanta subsidiary borrowed $616 million under its credit facilities, funding the rest with cash on hand and a recent $300 million equity raise. The deal roughly doubles Novanta’s recurring medical consumables revenue to about $300 million. (Link)
  13. Serelora, Inc. acquired the clinical risk-stratification software of ACTIN Care Groups to extend its agentic EHR into population-level analysis. Serelora, a company building an AI-native agentic electronic health record, acquired the clinical risk-stratification software of ACTIN Care Groups. Financial terms were undisclosed, and both companies are privately held. The acquired technology includes WellCheck, a 27-instrument preventive risk battery assessing clinical, behavioral and social risk factors, which becomes a native capability of Serelora’s record. Co-founder and CTO Spencer Wozniak framed the deal as extending the system’s intelligence from the individual chart to whole populations, letting organizations identify who is trending toward risk. The acquisition moves Serelora beyond documentation into population health analytics inside the same agentic system clinicians already use. (Link)
  14. Quasar Medical acquired Medres International’s Nitinol Design and Development Center in San Diego to expand its minimally invasive device manufacturing platform. Quasar Medical, a global contract development and manufacturing organization specializing in minimally invasive devices, acquired the Medres Nitinol Design and Development Center in Carlsbad, California. Financial terms were undisclosed. The transaction covers the 10,000-square-foot facility established in 2024, its engineering talent, manufacturing capabilities and customer relationships. Both parties are private. The site becomes Quasar’s dedicated nitinol center under SVP of Technology Christine Trepanier, complementing hubs in Israel and Galway and sitting an hour from Quasar’s Tecate, Mexico production facility. Medres International retains its remaining business. The deal deepens Quasar’s exposure to nitinol, a widely used enabling material for implantable and disposable devices. (Link)
  15. Transform Health Partners completed an acquisition of Sound Surgeons to expand its platform. Transform Health Partners acquired Sound Surgeons, a bariatric and weight-loss surgery practice, along with Sound Weight & Wellness in Washington state. The deal extends the buyer’s strategy of adding medical facility assets to its portfolio, with a focus on outpatient weight-loss and bariatric services. (Link)
  16. Timshel Health, LLC added Texas-based MyMD Select to its national direct primary care holding company to open new clinics across Texas. MyMD Select, an East Texas direct primary care practice founded in 2014 by Jeremy Smith, MD, joined Timshel Health, a national holding company of direct primary care practices. Financial terms were undisclosed, and both companies are private. MyMD Select guarantees members all-hours access and same- or next-day appointments through functional-medicine-trained providers, and partners with employers to lower spending on labs, imaging and downstream care. With Timshel’s backing, MyMD Select plans to open new clinics throughout Texas. Timshel CEO Mac Findlay framed the deal as helping the practice scale while preserving its culture; Smith becomes MyMD Select’s chief medical officer. (Link)
  17. Private investor acquires Lampert’s Home Therapy A private investor acquired Lampert’s Home Therapy, Inc., a therapist-owned provider of pediatric occupational, physical, and speech therapy services based in Largo, Florida. The company serves children and adults with developmental disabilities across West Central Florida through clinic, home, school, and community settings. Founded in 2000, Lampert’s delivers specialized programs including the TheraSuit Method. Financial terms were not disclosed. The transaction closed June 22, 2026. (Link)
  18. Processa Pharmaceuticals, Inc. (NASD: PCSA) acquired Vidya Therapeutics, Inc. in a stock-for-stock transaction alongside an oversubscribed ~$200 million private placement from a syndicate led by Bain Capital Life Sciences, RA Capital Management and Janus Henderson Investors. Processa (NASD: PCSA) acquired Vidya Therapeutics, adding BTK inhibitor VT-7208, and simultaneously secured approximately $200 million in gross proceeds through Series A preferred stock priced at $1,221.19 per share. The oversubscribed placement drew Bain Capital Life Sciences, Janus Henderson Investors, RA Capital Management, SilverArc Capital, ADAR1 Capital Management, Cormorant Asset Management, Integral Health Asset Management, Marshall Wace, Octagon Capital and Soleus Capital. Proceeds fund operations into the second half of 2029 and three parallel Phase 2 programs. Existing Processa holders are left owning roughly 0.9% on a fully diluted basis, reflecting heavy dilution driven by the incoming investor syndicate. (Link)
  19. Waldencast plc (NASD: WALD) completed the sale of its Obagi Medical dermatological skincare and aesthetics business to mid-market investor Bridgepoint in a transaction valued at up to $460 million. Waldencast (NASD: WALD) closed the divestiture of Obagi Medical to Bridgepoint on July 30, 2026, in a deal valued at up to $460 million. Consideration includes roughly $366 million in cash, $30 million in vendor notes ($10 million fixed, $20 million adjustable) and up to $64 million of earnout tied to 2026 non-injectables and 2027 injectables revenue. Preliminary pro forma total consideration is about $380 million, with net cash proceeds near $334 million. Waldencast used about $178 million at closing to repay its senior term loan, eliminating $135.8 million of long-term debt. The Jersey-incorporated company now focuses on growing Milk Makeup, which generated $110.4 million of 2025 net revenue. (Link)
  20. MiMedx Group, Inc. (NASD: MDXG) agreed to acquire Sanara MedTech Inc. (NASD: SMTI) in a cash-and-stock deal valued at about $350 million. MiMedx (NASD: MDXG) entered a definitive merger agreement to acquire Sanara MedTech (NASD: SMTI) at $35 per share, a total enterprise value of approximately $350 million. Sanara holders receive $33.00 in cash plus 0.4735 MiMedx shares each, a 46% premium to Sanara’s 30-day volume-weighted average price. MiMedx will fund the cash portion with cash on hand and a committed $300 million first lien senior secured term loan from Hayfin Capital Management. The deal combines MiMedx’s surgical portfolio with Sanara’s regenerative surgical technologies, targeting 2027 combined revenue above $400 million, adjusted EBITDA margins over 20% and $20 million-plus in synergies. Closing is expected by year-end, pending Sanara shareholder and regulatory approval. (Link)
  21. Scribe Therapeutics Inc. (NASD: SCTX) closed a $155.5 million IPO at $15.00 per share, with a concurrent private placement to Sanofi. Scribe Therapeutics (NASD: SCTX) completed its IPO, selling 9,867,000 shares at $15.00, including full exercise of the underwriters’ 1,287,000-share option. Aggregate gross proceeds reached about $155.51 million, a figure that includes a concurrent private placement in which strategic partner Sanofi bought 500,000 shares at the IPO price. The shares began trading on the Nasdaq Global Market under ticker SCTX. Scribe is a clinical-stage biotech developing CRISPR-based genetic medicines, with lead candidate STX-1150 targeting PCSK9 to reduce LDL-C. The company, co-founded by Nobel laureate Jennifer Doudna, holds strategic collaborations with Sanofi and Eli Lilly. (Link)
  22. Synlogic and Caldera Therapeutics announce merger agreement and concurrent private placement Synlogic, Inc. (OTC: SYBX) and privately held Caldera Therapeutics entered a definitive all-stock merger agreement. The combined company will operate as Caldera Therapeutics and intends to list on the Nasdaq Capital Market under the ticker CALD. Concurrently, Caldera secured commitments for an approximately $278 million private placement from a syndicate of healthcare institutional investors. Proceeds are expected to fund Phase 2 trials of CLD-423, a TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease, with cash runway projected into 2029. (Link)
  23. Thoma Bravo completed its majority-stake acquisition of French occupational health software leader padoa, with existing investors Five Arrows and Kamet Ventures reinvesting. Thoma Bravo, the world’s largest software-focused investment firm with more than $172 billion in assets under management, completed its investment in padoa, the European leader in occupational health, safety and prevention software. The investment was made through Thoma Bravo’s Europe Fund, with significant participation from padoa’s co-founders and existing shareholders Five Arrows (Rothschild & Co’s alternative assets arm) and Kamet Ventures. Thoma Bravo assumes majority control while CEO Cédric Mathorel and the executive team retain a substantial stake. The capital funds AI development, customer service expansion, product innovation and international growth, particularly across the DACH region. padoa had previously raised roughly €105 million pre-buyout. (Link)
  24. PetIQ acquires MYOS muscle health portfolio PetIQ, a leading pet health and wellness company and portfolio company of Bansk Group, acquired MYOS Corp and its Fortetropin-based portfolio of muscle health products for pets. The products support muscle preservation, injury recovery, and healthy aging in companion animals. Terms of the transaction were not disclosed. The acquisition expands PetIQ’s science-backed brand portfolio and strengthens its position in the growing pet health and wellness category. (Link)
  25. Latigo Biotherapeutics files for IPO Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing non-opioid pain medicines, filed an amended S-1 registration statement for its initial public offering. The company plans to offer 16 million shares of common stock, with an additional 2.4 million shares available to underwriters. The expected price range is $16.00 to $18.00 per share. Latigo has applied to list on the Nasdaq Global Select Market under the ticker LTGO. Its lead candidates are oral Nav1.8 inhibitors designed to stop pain transmission without addiction risk. (Link)
  26. Attovia Therapeutics files for IPO Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases, filed an amended S-1 registration statement for its initial public offering. The company plans to offer 12.5 million shares of common stock, with an additional 1.875 million shares available to underwriters for overallotments. The expected price range is $15.00 to $17.00 per share. Attovia has applied to list on the Nasdaq Global Market under the ticker ATTO. Proceeds will support clinical development of its ATTOBODY platform candidates. (Link)

Venture Deals and Other

  1. Function secured $450 million in non-dilutive growth financing from General Catalyst’s Customer Value Fund to scale its preventive health platform. Function, an Austin-based whole-body health company, closed $450 million in growth financing from General Catalyst’s Customer Value Fund, the firm’s non-dilutive vehicle that ties capital to customer growth rather than equity. General Catalyst manages a portfolio of 800-plus businesses. The financing follows Function’s $298 million Series B in November and its Q2 acquisitions of Getlabs’ nationwide blood-draw network and supplement platform SuppCo. Function offers 160-plus lab tests starting at $365 per year plus MRI and CT scanning across 200-plus locations, and reports 500,000-plus members. (Link)
  2. Healia, an Ohio-based healthcare benefits platform, raised a $14 million Series A led by 111° West Capital with participation from Y Combinator, First Round Capital, Pioneer Fund, GoAhead Ventures and Ohio-based North Coast Ventures. Healia, a Columbus, Ohio provider of a healthcare benefits platform for dual-income families and employers, raised $14 million in Series A funding led by 111° West Capital, bringing total funding to $18 million. Participating investors included Y Combinator, First Round Capital, Pioneer Fund, GoAhead Ventures and North Coast Ventures, a Cleveland, Ohio venture firm. Led by founder and CEO Priyang Shah, Healia builds health reimbursement arrangements that let employers cover employee healthcare costs and premiums when workers enroll in a spouse’s plan. Its platform compares plan options on total cost of ownership, facilitates spousal-plan enrollment and automates claims to reimburse expenses within hours. Proceeds fund operations and product development. (Link)
  3. Flourish Health raised $46 million, with a $26 million Series A led by B Capital, F-Prime and Cherryrock Capital, to scale intensive youth mental health care. Flourish Health, a Richmond, Virginia mental health provider for young people with serious, complex needs, announced $26 million in Series A funding led by B Capital, F-Prime and Cherryrock Capital, which combined with $20 million in previously undisclosed funding brings total capital raised to $46 million. The Series A investors are backing a psychiatrist-led, in-home model delivered through four-person Care Pods and a proprietary AI workflow platform. Studies with major health plans showed 70–96% reductions in hospitalizations and 69–90% reductions in residential treatment. The new capital funds national expansion in partnership with large health plans, platform investment and clinician hiring. (Link)
  4. Doctronic acquired pediatric telehealth company Summer Health, building on its $40 million Series B round backed capital base. Doctronic, an AI-enabled doctor consultation platform, acquired Summer Health, a text-based pediatric telehealth company, to extend primary care to children from birth. Deal terms were undisclosed; both companies are private. Doctronic raised $40 million in Series B funding in March, bringing total funding to $65 million, part of which was earmarked for pediatric expansion. Summer Health, founded in 2022, had raised $11.65 million in Series A funding in 2024 after an earlier $7.5 million round, and has supported more than 100,000 pediatric encounters. Doctronic plans to use Summer Health’s repository of 100,000-plus pediatric conversations to develop pediatric-specific AI models; founder Ellen DaSilva joins to lead B2B growth. (Link)
  5. Epitel, Inc. secured a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures to expand its wireless remote EEG monitoring system. Epitel, a Salt Lake City AI-driven wireless brain health company, closed a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures, with new and existing investors participating. The capital funds commercial expansion of its REMI Remote EEG Monitoring System, a fully wireless FDA-cleared platform that pairs wearable sensors with AI-driven seizure detection for at-home monitoring over several weeks. The REMI portfolio holds five FDA 510(k) clearances and is cleared for patients as young as one year old. Proceeds scale sales, marketing and customer teams, streamline provider deployment and grow ambulatory market access. Joshua Phillips of Catalyst Health Ventures chairs Epitel’s board. (Link)
  6. Dopl Technologies raised a $6.3 million seed round led by SpringTide Ventures, with participation from WRF Capital, Tacoma Venture Fund, HeartX, Transform Health Ventures and Precursor Ventures. Dopl Technologies, a Bothell, Washington medical technology company developing a robotic ultrasound platform, raised $6.3 million in seed funding led by SpringTide Ventures, bringing total funding above $8 million. WRF Capital, Tacoma Venture Fund, HeartX, Transform Health Ventures, Precursor Ventures and others participated. Led by CEO and co-founder Ryan James, PhD, Dopl combines robotics, AI and remote clinical expertise across its Traverse robotic ultrasound system, Dopl Connect data platform and SonoFlex distributed sonographer workforce tool. The company currently serves critical access hospitals across Washington State. Proceeds fund FDA clearance work, including product verification and validation, submission activities, clinical evaluation and initial market release. (Link)

CLICK HERE to sign up
for all news and updates